CCL26 and asthma: This reduction was sustained to the end of treatment in both studies: at week 52, the median percentage change from baseline in plasma eotaxin‐3 in dupilumab‐ versus placebo‐treated patients was −38.24% versus −0.16% in asthma patients and −51.47% versus 8.30% in CRSwNP patients (both p < .0001 versus placebo).